STL Index for: Dabrafenib
There are many new immunotherapeutics that have been approved or are in clinical and pre-clinical trials to expand our arsenal in the treatment of melanoma and other previously difficult to treat malignancies.
An overview and update of skin treatments introduced in 2014: Quick overview of drug name, indications and regulatory status. Clindamycin phosphate 1.2% + benzoyl peroxide 3.75% gel (Onexton™), Doxycycline hyclate tablets (Acticlate™), Tretinoin gel microsphere 0.08% (Retin-A Micro®) and many other drugs are covered.
An overview and update of skin treatments introduced in 2013: Quick overview of drug name, indications and regulatory status. Adapalene 0.1% + benzoyl peroxide 2.5% gel (Epiduo®), Ingenol mebutate gel (0.015%, 0.05%) (Picato®), Efinaconazole 10% topical solution (Jublia®) and many other drugs are covered.
Update on Dabrafenib mesilate capsule (Tafinlar™), Trametinib dimethyl sulfoxide tablet (Mekinist™), and Vismodegib capsule (Erivedge®)